Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

This open-label pilot study will evaluate safety and tolerability of a single 0.5 mg/kg IV ketamine infusion in older adults with mild cognitive impairment and clinically significant depression (MADRS ≥20).

Participants (n=15) undergo screening and baseline assessments including questionnaires, blood draw, cognitive testing, MRI (non-contrast) and optional EEG, receive one IV ketamine infusion, and are assessed at 1, 2, 3, 7, and 30 days post-infusion.

Primary outcomes are safety and tolerability; secondary and exploratory outcomes include changes in depression and cognition, imaging/connectivity measures, and the influence of amyloid biomarker status on response.